Publications by authors named "M Bryl"
Article Synopsis
- The POL-MOL study aimed to assess the use of molecular testing in Polish patients diagnosed with metastatic non-small cell lung cancer (NSCLC), as its extent was previously unknown.
- Oncologists completed questionnaires about molecular testing for various genetic mutations and PD-L1 assessment, collecting data from 1001 patients receiving systemic treatment.
- Results indicated that molecular tests were conducted in 78% of NSCLC patients, with higher testing rates in more advanced disease stages, and about 30% of tests in squamous cell carcinoma patients were positive for specific mutations.
Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC).
Patients And Methods: Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was the objective response rate.
Introduction: Positron emission tomography/computed tomography (PET/CT) has an established role in evaluating patients with lung cancer. The aim of this work was to assess the predictive capability of [F]Fluorodeoxyglucose ([F]FDG) PET/CT parameters on overall survival (OS) in lung cancer patients using an artificial neural network (ANN) in parallel with conventional statistical analysis.
Methods: Retrospective analysis was performed on a group of 165 lung cancer patients (98M, 67F).
Introduction: Pembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) and the expression of programmed death ligand 1 (PD-L1) in <50% of tumour cells (TC).
Methods: We evaluated the efficacy of the treatment in real-world practice, paying attention to the predictive factors, with a special focus on low level of PD-L1 expression. This study is a multicenter retrospective analysis of patients with stage IV NSCLC.
Lymphadenectomy is an essential part of complete surgical operation for non-small cell lung cancer (NSCLC). This retrospective, multicenter cohort study aimed to identify factors that influence the lymphadenectomy quality. Data were obtained from the Polish Lung Cancer Study Group Database.
View Article and Find Full Text PDF